Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)β’ Click on a phase to view related trials
Not Applicable
1 (50.0%)Phase 1
1 (50.0%)Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors
Not Applicable
Recruiting
- Conditions
- HER2-positive Advanced Malignant Solid Tumors
- Interventions
- Biological: Anti-HER2 CAR-T cells
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- UTC Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06658951
- Locations
- π¨π³
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
Phase 1
Recruiting
- Conditions
- Malignant MesotheliomaOvary CancerBreast Cancer FemaleBile Duct CancerPancreatic CancerColorectal CancerRectal Cancer
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- UTC Therapeutics Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06256055
- Locations
- π¨π³
Peking University Cancer Hospital & Institute, Beijing, China
News
No news found